Target Information
General Information of This Target (ID: PATR0VPYPS)
| Target Name | Glucocorticoid receptor (NR3C1) |
|||||
|---|---|---|---|---|---|---|
| Gene Name | NR3C1 |
|||||
| Gene ID | ||||||
| Synonym | GRL; Nuclear receptor subfamily 3 group C member 1 |
|||||
| Sequence |
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK Click to Show/Hide
|
|||||
| Family | the nuclear hormone receptor family |
|||||
| Function |
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth.[Isoform Alpha]: Has transcriptional activation and repression activity. Mediates glucocorticoid-induced apoptosis. Promotes accurate chromosome segregation during mitosis. May act as a tumor suppressor. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression.[Isoform Beta]: Acts as a dominant negative inhibitor of isoform Alpha. Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed. Loses this transcription modulator function on its own. Has no hormone-binding activity. May play a role in controlling glucose metabolism by maintaining insulin sensitivity. Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner. Directly regulates STAT1 expression in isoform Alpha-independent manner.[Isoform Alpha-2]: Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism.[Isoform GR-P]: Increases activity of isoform Alpha.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Phase 2 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
ABBV-3373
|
Adalimumab |
Tumor necrosis factor (TNF) |
Glucocorticoid receptor modulator |
MP-Ala-Ala |
|
|
ABBV-154
|
Adalimumab |
Tumor necrosis factor (TNF) |
Glucocorticoid receptor modulator |
Formyl-Gly-Glu |
Phase 1
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
ABBV-319
|
Anti-CD19 IgG1 mAb |
B-lymphocyte antigen CD19 (CD19) |
Glucocorticoid receptor modulator |
MP-Ala-Ala |
|
|
DB-2304
|
Hu033-03 |
C-type lectin domain family 4 member C (CLEC4C) |
P2025 |
A cleavable linker |
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Anti-TNF ADC 121
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 17 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 126
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 20 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 127
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 25 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 128
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 26 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 129
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 30 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 131
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 31 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 134
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 64 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 104
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 5 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 105
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 16 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 106
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 17 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 107
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 18 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 108
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 19 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 109
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 20 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 110
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 22 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 111
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 23 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 112
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 24 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 113
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 25 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 114
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 26 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 115
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 30 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 116
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 31 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 117
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 33 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 118
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 61 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 119
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 5 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 120
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 5 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 123
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 19 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 124
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 19 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 125
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 20 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 130
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 31 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 132
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 32 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 133
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 32 |
MP-Ala-Ala |
|
|
Anti-TNF ADC 135
[1]
|
Anti-TNF mAb alpha-TNF |
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) |
GRM cpd 63 |
MP-Ala-Ala |
|
|
Anti-PRLR-Ab-LP2-P12
[2]
|
Anti-PRLR mAb |
Prolactin receptor (PRLR) |
Budesonide derivative P12 |
DIBAC-suc-PEG4-Val-Cit-PAB |
|
|
Anti-PRLR-Ab-LP1-P3
[2]
|
Anti-PRLR mAb |
Prolactin receptor (PRLR) |
Budesonide derivative P3 |
DIBAC-suc-PEG4-Val-Cit-PAB |
|
|
Cymac-001
[3]
|
Undisclosed |
Scavenger receptor cysteine-rich type 1 protein M130 (CD163) |
Dexamethasone |
Undisclosed |
|
|
CD70-glucocorticoid ADC
[4]
|
Undisclosed |
CD70 antigen (CD70) |
Fluticasone propionate |
Pyrophosphate linker |
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Anti-CD11a_VCGP-Dex
[5]
|
Efalizumab |
Integrin alpha-L (ITGAL) |
Dexamethasone |
Mal-ValCitGlyPro-OH |
|
|
Anti-CD38_VCGP-Dex
[5]
|
Daratumumab |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) |
Dexamethasone |
Mal-ValCitGlyPro-OH |
|
|
Anti-TNFalpha_VCGP-Dex
[5]
|
Adalimumab |
Tumor necrosis factor (TNF) |
Dexamethasone |
Mal-ValCitGlyPro-OH |
|
|
Anti-HER2_VCGP-Dex
[5]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Dexamethasone |
Mal-ValCitGlyPro-OH |
|
|
Anti-RSV_VCGP-Dex
[5]
|
Palivizumab |
Respiratory syncytial virus fusion glycoprotein (RSV F protein) |
Dexamethasone |
Mal-ValCitGlyPro-OH |
|
|
INX201J
[6]
|
INX201 |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR) |
Cpd 2 |
Cys linker |
|
|
INX231J
[6]
|
INX231 |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR) |
Cpd 2 |
Cys linker |
|
|
INX234J
[6]
|
INX234 |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR) |
Cpd 2 |
JP2024502360A5 INX201N Linker |
|
|
INX240J
[6]
|
INX240 |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR) |
Cpd 2 |
JP2024502360A5 INX201N Linker |
|
|
CD44-DXTS
[7]
|
Undisclosed |
CD44 antigen (CD44) |
Dexamethasone |
3-Maleimidopropionic acid linker |
|
|
SHR-4597
|
Anti-IL-4Rα antibody |
Interleukin-4 receptor subunit alpha isoform 2 precursor |
Budesonide |
Mc-PEG3-Gly-Gly-Phe-Gly |
|
|
LFD-200
|
Anti-VISTA antibody |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR) |
Undisclosed |
Undisclosed |
References
